Sun Pharma arm signs licensing agreement with Aclaris Therapeutics
The agreement includes an upfront payment of USD 15 million, regulatory and commercial milestones, and royalties.
Wayne: Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, has announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc..
Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
The agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties. Aclaris exclusively licenses the patents from a third party, and has separate contractual obligations under which it owes a portion of the consideration received from Sun Pharma.
“We are pleased to announce this patent license agreement with Sun Pharma, which represents our second out-license for this patent portfolio,” stated James Loerop, Chief Business Officer of Aclaris.
Read also: Sun Pharma granted exemption from excise duty on Danazol
Read also: Sun Pharma, WOTR to create over 5.2 billion litres of water harvesting capacity in rural Maharashtra
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.
Read also: Sun Pharma gets CDSCO nod to manufacture, market FDC Silodosin JP plus Tadalafil
